NASDAQ: AXSM

Axsome Therapeutics (AXSM) Stock Analysis & Forecast

Nov 13 close

$141.69−2.68 (−1.9%)

Gekko Brief

AI summaryNov 9 close

Axsome Therapeutics this week centered on third-quarter results and analyst reaction. Revenue grew 52% year-over-year to $260 million, with AUVELITY contributing $208 million in net sales and SUNOSI adding $48.2 million, while EPS of $-0.25 beat estimates. Following the report, UBS adjusted its price target to $239 from $256 while maintaining a Buy rating, and management participated in the Guggenheim Healthcare Innovation Conference and other investor events during the month.

Shares closed at $133.96, up 1.2%, but remain below both the 50-day average of $176.31 and the 200-day average of $197.88, with the 50-day sitting below the 200-day. Over the past month the stock has returned -20.4%, and over six months -38.1%. The GekkoIndex reads 69.9, placing the stock in the Accumulation zone, while the price sits 36.7% below the Gekko Fair Value of $211.58.

The next earnings date falls on 22 February 2027, outside a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows. Seasonality data from this point in the calendar shows the next 20 trading days averaging +7.2% over 5 years, with gains in 4 of those years. Analyst sentiment remains broadly positive, with 18 of 19 firms rating the stock Buy and a consensus target of $271.05.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Axsome Therapeutics price vs fair value

$206.85$141.69Nov ’25May ’26Nov ’26
Close $141.69200-day averageGekko Fair Value $206.85

Axsome Therapeutics quick facts

Market cap
$7.45B
P/E ratio
—
Forward P/E
29.3
EPS, TTM
−$3.03
Revenue, TTM
$865.3M
Profit margin
-18.2%
Dividend yield
—
Beta
0.83
Volume
888,642 avg 1.12M
1-year return
+0.6%
Typical daily move
±5.9%
Typical 20-day move
±9.7%
50-day average
$171.45
200-day average
$197.05
Next earnings
Feb 22 before open
Shares outstanding
52.60M
52-week range
$123.00$260.19

Axsome Therapeutics swing-trade checklist

Axsome Therapeutics scores 4 supportive, 0 mixed and 1 headwind across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

4 supportive0 mixed1 headwind

  • Trendheadwind

    Below 50 and 200-day

    Close $141.69 is below the 50-day ($171.45) and 200-day ($197.05) averages, and the 50-day is below the 200-day.

    See the chart
  • GekkoIndexsupportive

    62.6, Accumulation

    Reading 62.6 is in the Accumulation zone.

    See the GekkoIndex
  • Fair valuesupportive

    31.5% below

    Price is 31.5% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 99 days

    Next report Feb 22, 2027, 99 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +8.9% on average

    From this point in the calendar, the next 20 trading days averaged +8.9% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Axsome Therapeutics stock chart and price history

Axsome Therapeutics closed at $141.69 on Nov 13, 2026, +0.6% over the past year, inside a 52-week range of $123.00 to $260.19.

Close50-day average200-day averageVolume
Axsome Therapeutics share price, past year, with 50-day and 200-day moving averages and volume$200$250DecJan 2026FebMarAprMayJunJulAugSepOctNov141.69

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−12.4%
3 months
−34.5%
6 months
−37.8%
1 year
+0.6%
The full AXSM chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open AXSM in Gekko

Follow Axsome Therapeutics through every session

Put AXSM on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track AXSM in GekkoFree for 7 days. No credit card required.

About Axsome Therapeutics

Axsome Therapeutics works on developing treatments for disorders of the central nervous system, focused on patients in the United States. The company is best known for its pipeline of investigational drugs targeting conditions such as depression, Alzheimer's-related agitation, migraine, narcolepsy and fibromyalgia, with several candidates moving through Phase III trials at various stages of study.

Its work centers on advancing these compounds through clinical development rather than selling approved products, with each candidate aimed at a specific CNS condition. Axsome Therapeutics also collaborates with Duke University to study one of its compounds for use in smoking cessation, extending the potential applications of its research beyond the primary conditions it targets.

The company was founded in 2012 and is headquartered in New York, New York. Its shares trade on the NASDAQ under the ticker AXSM.

Listed
NASDAQ
Sector
Health technology
Industry
Biotechnology
Website
axsome.com

Axsome Therapeutics GekkoIndex: the smart money zone

Axsome Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 62.6, in the Accumulation zone, down 9.3 points over five sessions.

010062.6Accumulation

Down 9.3 points over five sessions, from the Buying zone.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying42−2.1%−3.6%+0.6%+16.9%
Accumulation (current zone)187+0.4%+1.2%+3.2%+9.9%
Neutral416+0.8%+1.1%+2.3%+7.1%
Distribution53+0.2%+2.0%−1.0%+0.3%
Selling4Too few readings yet

Average AXSM share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.

Accumulation zone: Institutional interest building. About the five zones →

See every daily GekkoIndex reading plotted over the AXSM price, zone by zone.Track AXSM in Gekko

Is Axsome Therapeutics stock overvalued? Gekko Fair Value

Axsome Therapeutics trades 31.5% below Gekko Fair Value of $206.85, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Axsome Therapeutics shares are worth, recalculated every trading day.

$206.85

Gekko Fair Value, Nov 14, 2026

31.5% Undervalued

At the end of Aug 2026 the price was 25.0% below the estimate.

Gekko Fair ValueShare price, month end
$207$142Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open AXSM in Gekko

Axsome Therapeutics insider and Congress trading

No open-market insider purchases were filed for Axsome Therapeutics, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for AXSM in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every AXSM insider filing, plotted on the chart in Gekko.Open AXSM in Gekko

Congress trades last 90 days

No trades in AXSM were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for AXSM, plotted on the chart in Gekko.Open AXSM in Gekko

Hedge funds and billionaires quarter ended Mar 31

0of the funds Gekko tracks hold AXSM.

0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko

Axsome Therapeutics earnings: next date and track record

Axsome Therapeutics reports on Feb 22, 2027, before the open (99 days away), and beat the EPS estimate in 5 of its last 8 reports.

5 of 8reports beat the EPS estimate
±3%average move across the report
3 of 8reports followed by a gain

Share-price move across each report

−3.2%Feb ’250.0%May ’25+0.6%Aug ’250.0%Nov ’25−7.5%Feb ’26+8.0%May ’26+1.4%Aug ’26−3.3%Nov ’26

Last earnings call, Nov 2, 2026 AI summary

What they said
Axsome reported Q3 total revenue of $260 million, up 52% year-over-year and 19% sequentially. AUVELITY led with $208 million in net sales (+53% YoY), driven by MDD demand and Alzheimer's disease agitation expansion. SUNOSI generated $48.2 million (+47% YoY) while SYMBRAVO posted $3.9 million (+88% YoY). Net loss narrowed to $12.9 million ($0.25/share) vs. $47.2 million prior year, demonstrating improving operating leverage.
Guidance
Management expects sustained AUVELITY momentum from MDD demand growth and Alzheimer's agitation acceleration. Gross-net discounts for AUVELITY and SUNOSI anticipated to increase slightly in Q4 due to seasonality. Current $314 million cash balance expected sufficient to fund operations through cash flow positivity.
ReportedEPSSurpriseRevenueSurpriseMove
Nov 2, 2026−$0.25
est −$0.63
+60.6%$259.7M
est $249.2M
+4.2%−3.3%
Aug 10, 2026−$0.99
est −$0.89
−11.0%$216.4M
est $221.1M
−2.2%+1.4%
May 4, 2026−$1.26
est −$0.86
−46.5%$189.4M
est $190.9M
−0.8%+8.0%
Feb 23, 2026−$0.56
est −$0.73
+22.8%$194.7M
est $193.4M
+0.7%−7.5%
Nov 3, 2025−$0.94
est −$0.82
−14.6%$171.0M
est $191.3M
−10.6%0.0%
Aug 4, 2025−$0.92
est −$1.00
+8.0%$150.0M
est $140.0M
+7.2%+0.6%
May 5, 2025−$0.80
est −$1.26
+36.5%$121.5M
est $140.4M
−13.5%0.0%
Feb 18, 2025−$0.96
est −$1.00
+4.0%$118.8M
est $119.5M
−0.6%−3.2%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Axsome Therapeutics stock forecast and analyst price targets

Analysts’ average 12-month price target for Axsome Therapeutics is $265.86, +87.6% from the last close, from 19 firms rating the stock in the last 90 days.

$265.86consensus 12-month target, +87.6% from the last close
Low $135High $310
Buy18
Hold1
Sell0

Each firm’s latest rating in the last 90 days: 19 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 13Morgan StanleyHold, maintained$223+57.4%
Nov 9H.C. WainwrightBuy, reiterated$290+104.7%
Nov 4Mizuho SecuritiesBuy, maintained$272+92.0%
Nov 3UBSBuy, reiterated$239+68.7%
Nov 3Robert W. BairdBuy, maintained$220+55.3%
+3.2%average 20-day move after past Accumulation readings
+8.9%average move over the next 20 trading days in the last 5 years
±5.9%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Axsome Therapeutics seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Axsome Therapeutics averaged +8.9% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

−20.2%2021+44.9%2022+18.8%2023−7.5%2024+4.7%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−0.3%2 of 5
Next 10 trading days+6.8%4 of 5
Next 15 trading days+8.6%4 of 5
Next 20 trading days+8.9%3 of 5
Next 30 trading days+10.3%3 of 5

For scale, AXSM’s typical 20-trading-day move in either direction is about 9.7%.

Axsome Therapeutics market cap and key statistics

Axsome Therapeutics’s market cap is $7.45B and revenue of $865.3M over the last twelve months.

Valuation

Market cap
$7.45B
Forward P/E
29.3
EPS, TTM
−$3.03
Gekko Fair Value
$206.85

Trading

Volume
888,642
Avg volume, 20 days
1.12M
52-week high
$260.19
52-week low
$123.00
Shares outstanding
52.60M

Financials

Revenue, TTM
$865.3M
Profit margin
-18.2%
Return on equity
-175.6%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
0.83
Typical daily move
±5.9%
Typical 20-day move
±9.7%

Axsome Therapeutics peers

Axsome Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
AMGNAmgen−0.4%Neutral19.9% below
GILDGilead Sciences−0.3%Neutral11.7% above
MRNAModerna−0.7%Neutral21.1% above
NTRANatera−1.8%Accumulation18.6% below
IQVIQVIA−2.4%Accumulation5.0% above
UTHRUnited Therapeutics−0.4%Neutral11.2% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Biotechnology

Axsome Therapeutics stock FAQ

What is Axsome Therapeutics’s market cap?

Axsome Therapeutics’s market cap is $7.45B at the Nov 13, 2026 close of $141.69, with 52.60M shares outstanding.

What is the Axsome Therapeutics stock forecast?

The consensus analyst 12-month price target for Axsome Therapeutics is $265.86, +87.6% from the last close. Of the 19 firms that rated the stock in the last 90 days, 18 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Axsome Therapeutics stock overvalued or undervalued?

On Gekko’s estimate Axsome Therapeutics is undervalued: the Nov 13, 2026 close of $141.69 is 31.5% below Gekko Fair Value of $206.85. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Axsome Therapeutics report earnings next?

Axsome Therapeutics is expected to report on Feb 22, 2027, before the market opens (99 days away). Analysts expect earnings of −$0.05 per share on revenue of $284.0M. Axsome Therapeutics beat the earnings estimate in 5 of its last 8 reports, moving 3% on average across the report.

What is Axsome Therapeutics’s 52-week high and low?

Axsome Therapeutics’s 52-week high is $260.19 and its 52-week low is $123.00; it closed at $141.69 on Nov 13, 2026, +0.6% over the past year.

Is Axsome Therapeutics stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality) and 1 as a headwind (trend). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Axsome Therapeutics the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.